The shares of commercial-stage medical tool maker Ra Medical Systems (RMED) have actually tumbled 92.7% in price over the past year due to capitalist issues bordering the company’s bad financial health and wellness. Additionally, given the uncertainty surrounding the FDA’s authorization of its DABRA catheter laser system, the concern becomes, is the penny stock a sure thing now? Keep reading, allow’s find out.

Medical tool company Ra Medical Systems, Inc. (RMED – Obtain Ranking) in Carlsbad, Calif., is designs, develops, and also markets excimer lasers to deal with vascular illness. The business has made considerable development in essential campaigns, including its DABRA technology laser system and also atherectomy critical medical study. Nevertheless, the RMED stock has actually decreased 86.8% in price over the past six months and 92.7% over the past year, showing investor concerns over its frustrating earnings as well as incomes growth and the sale of its dermatology company.

Closing the other day’s session at $0.42, the stock is currently trading 95.7% listed below its 52-week high of $9.82, showing bearish belief.

While the commercial-stage medical gadget company has submitted a 510( k) application with the united state Food and Drug Administration (FDA) for its DABRA catheter, its commercialization leads continue to be uncertain till its product receives authorization from the FDA. In addition, the stock’s negative productivity can make capitalists nervous.

Selling Shares

Last month, RMED priced an underwritten public offering of devices of its common stock, consisting of warrants to acquire up to 27.6 million shares of the common stock as well as pre-funded warrants to buy approximately 14.47 shares of penny stocks. The medical gadget maker anticipates roughly $12.1 million in gross proceeds from the offering.

Divestiture of Dermatology Business

Top 10 Stocks for 2022
In the 3rd quarter, RMED finished the sale of its Pharos dermatology service for web proceeds of approximately $3.5 million. This was done as a part of the company’s strategies to focus its sources on the market for medical gadgets to treat outer artery disease (PAD). However, the divestiture can adversely influence the medical tool manufacturer’s earnings as well as cost framework in the close to term as well as trigger RMED’s stock cost to roll additionally.

Stark Earnings

The firm’s trailing-12-month ROA and money from procedures are unfavorable 100.6% and $31.33 million, specifically. Furthermore, its trailing-12-month gross profit margin, ROE and also ROTC are negative 18.9%, 115%, as well as 67%, respectively. And also its 0.12% asset turn over ratio is 65.2% less than the 0.34% market average.

Faltering Financials
RMED’s internet earnings from continuing procedures can be found in at $5,000 for the 3rd quarter, ended Sept. 30, 2021, versus $68,000 in the 3rd quarter of 2020. Its gross loss stood at $24,000 for the quarter, while running loss was available in at $7.39 million. Additionally, its net loss totaled up to $4.3 million, while its loss per share came in at $0.67. RMED reported an unfavorable modified EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. As well as its complete operating budget grew 2.1% year-over-year to $7.15 million throughout this duration.

POWR Scores Show Bleak Potential Customers

RMED has a total D rating, which equates to Market in our POWR Rankings system. The POWR Ratings are determined by considering 118 distinct aspects, with each variable weighted to an optimal degree.

Our exclusive ranking system additionally examines each stock based on 8 unique groups. RMED has an F quality for Quality. This reflects the stock’s negative ROA as well as capital from procedures.

The firm has a D quality in Momentum, consistent with its rate decrease over the past six months. Also, it has an F grade for Stability, which is in sync with its reasonably high beta of 1.65.

Beyond the grades I have highlighted, one can look into added RMED ratings for Sentiment, Growth, as well as Worth below. Among the 166 stocks in the D-rated Medical– Instruments & Equipment industry, RMED is rated # 119.


Experts anticipate RMED’s EPS to continue to be negative this year. While its efforts to create DABRA catheters bode well, its negative revenue margin and also insufficient economic stamina can trigger its shares to decline additionally. Furthermore, the unpredictability bordering the regulatory clearance and also commercialization of its DABRA laser system could raise financiers’ worries. So, we assume it is best stayed clear of now.

Just How Does Ra Medical Systems (RMED) Stack Up Against its Peers?

While RMED has a total D (Market) score in our proprietary ranking system, one may wish to take into consideration having a look at its industry peers, Fonar Company (FONR – Get Score), Electromed, Inc. (ELMD – Get Rating), and also Abbott Laboratories (ABT – Get Ranking), having an A (Solid Buy) rating.